My Sanford Chart allows you secure online access to your personal health information and your child's health information. It's available anywhere you have internet access. There is no cost to you and registering is quick and simple.

Sign Up for My Sanford Chart
Study ID: CTSU S0931
Title:

EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study.

Description:

The purpose of this study is to see whether treatment with everolimus after surgery for kidney cancer will increase the time without cancer returning. Participants in this study have cancer of the kidney that has been surgically removed. The current standard treatment after surgery is careful monitoring with no immediate treatment. Studies suggest that one way kidney cancer may grow is chemical signaling through a protein named ┬┐mTOR┬┐. Everolimus is a drug that stops signaling through mTOR and may therefore stop the growth of kidney cancer. Everolimus is a drug currently approved for the treatment of patients with advanced or metastatic kidney cancer.

Location:
Bemidji Clinic, Bismarck Region, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD,Preston Steen, MD
Disease:
REN (Renal)
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list